Cell Therapy

Placental-based Treatment Improved Mobility in Patients affected by Intermittent Claudication

Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, announced positive top-line results from its multinational Phase II clinical study of PLX-PAD cells in the treatment of Intermittent Claudication (IC). PLX-PAD treatment reduced Incidence of revascularization and improved patients’ mobility. Study results also validate the design of Pluristem’s ongoing Pivotal Phase III study in CLI, a more severe stage of peripheral arterial disease (PAD) and confirm Pluristem’s proprietary
cancer

Placental Cells Significantly Inhibit Cancer Cell Growth in Newly Published Study

According to the peer-reviewed article in the journal Scientific Reports, placenta-derived cells called PLX cells, exhibit a strong inhibitory effect on various lines of breast, colorectal, kidney, liver, lung, muscle and skin cancers. The research was conducted over more than two years by Pluristem Therapeutics, Inc., a Haifa-based biotechnology company. The article titled “Human Placental-Derived Adherent Stromal Cells Co-Induced with TNF‑a and IFN‑g Inhibit Triple-Negative Breast Cancer in Nude Mouse Xenograft
Cell Therapy

$8.7 Million Awarded to Support Phase III Femoral Neck Fracture Trial by EU Horizon 2020 Program

Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, announced today that its Phase III study of PLX-PAD cells to support recovery following surgery for femoral neck fracture has been awarded an $8.7 million (7.4 million Euro) non-dilutive grant from the Horizon 2020 program, the European Union’s largest research and innovation program. Final approval of the grant is subject to the finalization of the consortium and Horizon 2020
Biotechnology Cell Therapy

Leading Cell Therapy Company Pluristem to Partner with Japan’s Sosei for Commercialization of Regenerative Medicines in Japan

In a major global regenerative medicine deal, Israel-based Pluristem Therapeutics and Japan’s Sosei CVC, the venture capital arm of Japanese biopharma company Sosei Group, agreed to form a joint venture (JV) to commercialize Pluristem’s PLX-PAD cells in Japan. The deal marks Pluristem’s commercial entry into Japan and expands Sosei’s pipeline into regenerative medicines. Pluristem has been active in the Japan market through discussions with, and applications to, Japan’s health regulatory
Cardiology

Late Stage Critical Limb Ischemia Study using Placental Cell Therapy Snags $8 Million Grant from Europe’s Horizon 2020 Program

The European Union awarded an $8 million grant to cell therapy developer, Pluristem Therapeutics Inc., earmarked for a late stage trial in critical limb ischemia (CLI) program. The grant is part of the European Union’s Horizon 2020 program, which is its largest Research and Innovation program. The Phase III study of PLX-PAD in CLI will be a collaborative project carried out by an international consortium led by the Berlin-Brandenburg Center